新闻
ARDX
--
0.00%
--
东湾制药商在 FDA 拒绝后裁员 102 人
As it cut two-thirds of its positions, the company also outlined hundreds of thousands of dollars in cash and stock awards to retain three top executives.
American City Business Journals · 5天前
Brief-Ardelyx Inc 在与 FDA 的 A 类会议后提供公司更新
reuters.com · 5天前
Ardelyx 表示在 A 类会议上与 FDA 会面,但没有提供足够的清晰度关于什么构成“治疗效果大小的临床相关性”;等待有关 Tenapanor NDA 路径的更多信息
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal
Benzinga · 5天前
肠易激综合征药物市场-发展分析、进展状况、增长动力和挑战、到 2029 年的收入预期
Research Nester published a report titled which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.
AmericaNewsHour · 10/07 07:39
越来越多的胃肠道疾病为全球憩室炎药物市场创造增长机会,以在 2021-2029 年期间记录显着的复合年增长率
Research Nester published a report titled "" which delivers detailed overview of the global diverticulitis drugs market in terms of market segmentation by drug type, route of administration, distribution channel, end-user and by region.
AmericaNewsHour · 09/27 17:31
全球憩室炎药物市场增加胃肠道疾病,为 2029 年之前的市场创造增长机会
Research Nester published a report titled "" which delivers detailed overview of the global diverticulitis drugs market in terms of market segmentation by drug type, route of administration, distribution channel, end-user and by region.
AmericaNewsHour · 09/20 10:22
不幸的是,Ardelyx(纳斯达克股票代码:ARDX)的投资者在过去五年中损失了 89%
Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...
Simply Wall St. · 09/20 10:21
2 把落下的刀抓住
GuruFocus News · 09/17 15:37
肠易激综合征药物市场:预计复合年增长率、该地区和全球的顶级制造商和消费者分析、到 2029 年的机会和增长
Research Nester published a report titled which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.
AmericaNewsHour · 09/08 06:26
ARDX 截止日期提醒:Kessler Topaz Meltzer & Check, LLP - Ardelyx Inc. 投资者的重要截止日期提醒 2021 年 10 月 4 日
Radnor, Pennsylvania--(Newsfile Corp. - September 4, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Ardelyx Inc. (NASDAQ: ARDX) ("Ardelyx") investors that a securities fraud class action lawsuit has been filed against Ardelyx on behalf ...
Newsfile · 09/04 22:25
肠易激综合征药物市场 - 2029 年全球最新统计数据、发展领域和新兴机会
Research Nester published a report titled which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.
AmericaNewsHour · 09/03 13:51
BRIEF-Ardelyx Announces Publication Of 52-Week Phase 3 PHREEDOM Trial
reuters.com · 09/03 12:08
Ardelyx 重点发布为期 52 周的第 3 阶段 PHREEDOM 试验
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal
Benzinga · 09/03 12:01
Ardelyx 宣布发布为期 52 周的第 3 阶段 PHREEDOM 试验
and , /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today...
PR Newswire - PRF · 09/03 12:00
Ardelyx 公布高达 1.5 亿美元的普通股发行计划
MT Newswires · 08/18 06:27
The Daily Biotech Pulse:礼来重组神经科学业务部门,Helius Medical 获得突破性指定,Ra Medical 出售皮肤科业务
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
周一触及 52 周低点的股票
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
UWM Holdings、Paysafe、TuSimple 是上市前的失败者
China Finance Online JRJC -43% after receiving Nasdaq delisting notice and announces private placement of ordinary shares and warrants Sesen Bio SESN -36% after FDA declines to approve Sesen Bio's Vicineum bladder cancer treatment Standard
Seekingalpha · 08/16 12:59
期权市场是否会预测 Ardelyx (ARDX) 股票的飙升?
Zacks.com · 08/16 12:48
--Wedbush 将 Ardelyx 的目标价格从 Tenapanor 时间表、公司重组的 3 美元上调至 2 美元;保持中性评级
MT Newswires · 08/16 06:52
微牛提供丰富的实时ARDX股票新闻,让你可以通过多个平台了解ARDX股票行情最新动态,这些免费的Ardelyx新闻可以帮助你做出明智投资。
ARDX 简况
Ardelyx, Inc是一家生物制药公司,专注于药物的发现、开发和商业化,以改善肾脏和心肾疾病患者的治疗。该公司的产品线包括Tenapanor、IBSRELA、RDX013程序和RDX020程序。Tenapanor是一种用于控制成年慢性肾病(CKD)透析患者血清磷的药物。用于控制血清磷的Tenapanor具有作用机制,并在肠道局部起作用以抑制钠氢交换剂3(NHE3)。IBSRELA是为治疗便秘型肠易激综合征(IBS-C)患者而开发的。RDX013程序是一种小分子钾促分泌剂程序,用于潜在治疗高钾血症。RDX020程序是一种治疗代谢性酸中毒的小分子药物。该公司拥有一个药物开发计划,旨在抑制肠道碳酸氢盐交换以治疗代谢性酸中毒。